AnaptysBio, Inc.
ANAB
$19.87
$0.040.20%
| Weiss Ratings | ANAB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | ANAB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Good | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | ANAB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.03 | |||
| Price History | ANAB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -2.09% | |||
| 30-Day Total Return | -17.30% | |||
| 60-Day Total Return | -12.28% | |||
| 90-Day Total Return | 28.38% | |||
| Year to Date Total Return | -2.86% | |||
| 1-Year Total Return | -5.22% | |||
| 2-Year Total Return | -5.22% | |||
| 3-Year Total Return | -3.08% | |||
| 5-Year Total Return | -71.51% | |||
| 52-Week High % Change | -21.93% | |||
| 52-Week Low % Change | 60.70% | |||
| Price | ANAB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $27.50 | |||
| 52-Week Low Price | $13.36 | |||
| 52-Week Low Price (Date) | Nov 28, 2023 | |||
| 52-Week High Price (Date) | Feb 26, 2024 | |||
| Valuation | ANAB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 574.60M | |||
| Enterprise Value | 512.32M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -6.08 | |||
| Earnings Per Share Growth | 32.78% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 33.27 | |||
| Price/Book (Q) | 6.48 | |||
| Enterprise Value/Revenue (TTM) | 29.86 | |||
| Price | $21.08 | |||
| Enterprise Value/EBITDA (TTM) | -3.28 | |||
| Enterprise Value/EBIT | -3.26 | |||
| Market Cap Category | Small Cap | |||
| Dividends and Shares | ANAB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 26.59M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | ANAB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 858 362 6295 | |||
| Address | 10770 Wateridge Circle San Diego, CA 92121-5801 | |||
| Website | www.anaptysbio.com | |||
| Country | United States | |||
| Year Founded | 2005 | |||
| Profitability | ANAB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -915.49% | |||
| Profit Margin | -953.65% | |||
| Management Effectiveness | ANAB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -18.47% | |||
| Return on Equity | -- | |||
| Income Statement | ANAB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 17.16M | |||
| Total Revenue (TTM) | 17.16M | |||
| Revenue Per Share | $0.65 | |||
| Gross Profit (TTM) | -115.13M | |||
| EBITDA (TTM) | -156.42M | |||
| EBIT (TTM) | -157.07M | |||
| Net Income (TTM) | -163.62M | |||
| Net Income Avl. to Common (TTM) | -163.62M | |||
| Total Revenue Growth (Q YOY) | 32.27% | |||
| Earnings Growth (Q YOY) | -59.81% | |||
| EPS Diluted (TTM) | -6.08 | |||
| EPS Diluted Growth (Q YOY) | -70.17% | |||
| Balance Sheet | ANAB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 390.90M | |||
| Cash Per Share (Q) | $14.70 | |||
| Total Current Assets (Q) | 406.84M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 88.10M | |||
| Current Ratio (Q) | 10.866 | |||
| Book Value Per Share (Q) | $3.31 | |||
| Total Assets (Q) | 452.39M | |||
| Total Current Liabilities (Q) | 37.44M | |||
| Total Debt (Q) | 328.62M | |||
| Total Liabilities (Q) | 364.29M | |||
| Total Common Equity (Q) | 88.10M | |||
| Cash Flow | ANAB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | 144.75M | |||
| Cash from Financing (TTM) | -59.30M | |||
| Net Change in Cash (TTM) | -35.34M | |||
| Levered Free Cash Flow (TTM) | -73.42M | |||
| Cash from Operations (TTM) | -120.80M | |||
